The OhmX RAMP UP Grant Awarded to 15 Laboratories to Advance Genomic Research
PROVIDENCE, R.I., Feb. 21, 2025 /CNW/ -- Nabsys 2.0, LLC (Nabsys) and Hitachi High-Tech America, Inc. (HTA) have revealed the awardees of their OhmX Rapid Application to Market Penetration User Partnership, or OhmX RAMP UP, Grant Program. The program is focused on making structural variation detection more accessible to human genomics researchers by providing Nabsys' OhmX platform on consignment to selected labs.
Fifteen (15) RAMP UP grants were awarded in total, with participants currently progressing through various stages of the consignment agreement process. Upon completion, participants will use the OhmX platform to analyze structural variants (SVs) for various applications, including rare disease, cancer, and cell and gene therapy. Some specific applications include the analysis of repeat expansions, orthogonal confirmation of long-read sequencing calls, determining detection sensitivity for rare SVs, and enhanced cytogenetic profiling.
'I look forward to establishing electronic genome mapping as a core service for the Boston Children's Hospital research community. The technology seems promising for high-resolution analysis of structural variants' said Dr. Catherine Brownstein, a RAMP UP recipient at Boston Children's Hospital and Director of the Genomics Core.
The institutions participating in the program include:
Ann & Robert H. Lurie Children's Hospital of Chicago (Dr. Miriam Bornhorst)
Be Biopharma (Dr. Huei-Mei Chen)
Boston Children's Hospital (Dr. Catherine Brownstein)
Brigham and Women's Hospital (Dr. Phillip Michaels)
Drexel University (Dr. Ming Xiao)
Labcorp (Dr. Adam C. Smith)
Seattle Children's Hospital (Dr. Cate Paschal and Dr. Anica Wandler)
Stanford University (Dr. Alexander E. Urban)
Texas A&M University (Dr. Kenneth S. Ramos)
The Jackson Laboratory (Dr. Mark Adams, Dr. Charles Lee, Dr. Feyza Yilmaz)
The Translational and Advanced Medicine Center (Dr. Kevin P. Clancy)
University of Florida (Dr. Eric Wang)
Yale University (Dr. Ryan B. Jensen)
'Collaborations through the OhmX RAMP UP Grant Program represent our commitment to advancing genomic research by empowering the world's leading institutions with cutting-edge technology,' said Craig Kerkove, President & CEO, HTA. 'We are proud to support the groundbreaking work of these researchers, who are at the forefront of understanding and addressing the complexities of genetic diseases and cancer.'
'In awarding OhmX instruments to these prestigious laboratories, we have made a significant step forward in our mission to democratize access to genomic tools,' noted Nabsys CEO, Dr. Barrett Bready. 'This collaboration between Nabsys and HTA exemplifies our shared vision of powering innovation to drive transformative advancements in genomics and healthcare.'
OhmX's electronic nanochannel-based platform allows researchers to conduct targeted and whole-genome structural-variant analysis, leading to a better understanding of disease mechanisms, gene disruption, and complex genomic regions. This improved understanding empowers precision medicine with the potential to create more effective and personalized treatments, while also overcoming the cost and complexity barriers that are typically associated with SV analysis.
About Nabsys 2.0, LLC
The Nabsys 2.0, LLC ('Nabsys') mission is to advance the understanding of disease, increase diagnostic yield, and improve patient outcomes by enabling routine, accurate, cost-effective analysis of genomic structural variation. Located in Providence, RI, Nabsys employs a growing interdisciplinary group of dedicated scientists, engineers, and other professionals committed to the advancement of genomic analysis. For more information, visit https://www.nabsys.com.
About Hitachi High-Tech America, Inc.
Hitachi High-Tech America, Inc. (HTA) is a privately-owned global affiliate company that operates within the Hitachi Group companies. HTA sells and services semiconductor manufacturing equipment, analytical instrumentation, scientific instruments, and bio-related products, as well as industrial equipment, and electronic and industrial materials. HTA is dedicated to successful and profitable collaboration with leading companies worldwide, with a direction towards providing customers with superior quality products and services at fair and competitive prices. For more information, please visit https://www.hitachi-hightech.com/us/en.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Travel Weekly
4 days ago
- Travel Weekly
Inside the $6 million marketing campaign aimed at Maui's tourism recovery
Christine Hitt With Maui's visitor arrivals still 21% below prepandemic levels, the Hawaii Tourism Authority (HTA) and the Hawaii Visitors and Convention Bureau (HVCB) released details about a new $6 million marketing campaign aimed at supporting Maui's tourism recovery. The campaign features a national wholesaler program, an initiative that prioritizes selling Maui vacation packages, and doing so through partnerships with ALG/Apple Vacations, Classic Vacations, Costco Travel, Pleasant Holidays, Delta Vacations and Expedia. The wholesaler program requires exclusive consumer offers of a minimum 20% in value (such as fifth night free) to incentivize bookings. Wholesalers need to provide a 1:1 match of the HTA's investment, meaning they essentially double their marketing budget with the HTA's support. Marketing efforts include targeted campaigns showcasing Maui to specific destinations through media, social media and PR efforts. Additionally, the HVCB will be "amplifying its Hawaii Special Offers Program with conversion-focused paid and owned media and supporting the Maui Nui Kakou Multi-Market initiative," which includes a "Maui Week" campaign airing across 15 key markets. The "Maui Week" campaign is a takeover of lifestyle morning shows across the continental U.S. that spotlights five Maui properties over five days. Some of the key markets include Los Angeles, San Francisco, Chicago, New York and Portland. "It is indeed a privilege to lead this effort alongside our government partners, the visitor industry, and community voices," HVCB CEO Aaron Sala said in a news release. "With urgency and clear intention, we are working to deliver meaningful results for Maui's families and local businesses. This campaign is an important initial step in addressing an immediate need. Our larger journey continues — shaping the way we welcome people into relationship with Hawaii in ways that honor both community and place." The campaign was funded by the $6.3 million released by Gov. Josh Green in February for the purpose of boosting Maui's recovery efforts and increasing the number of visitors to the state overall.
Yahoo
5 days ago
- Yahoo
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
Emerging Biomarkers in the Clinical Development of Epilepsy Medicines and OV329 Program Highlights NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor and media event on Thursday, June 12, 2025, on the topic of applying Biomarkers in Epilepsy, including their strategic use to demonstrate the pharmacodynamic activity of the Company's OV329 clinical development program. World-leading expert, Dr. Alexander Rotenberg will join company management to discuss the emerging use of a wide range of biomarkers for the study of anti-seizure medicines. The event will take place at Ovid's headquarters in New York's Hudson Yards from 9:30 to 10:30 am ET and will be webcast simultaneously. Sophisticated imaging and radiological tools are increasingly enabling medicines developers to leverage biomarkers earlier in clinical development to identify signals of biological target engagement and pharmacodynamic activity. Discussion will focus on how these tools drive evidence informed approaches in drug development and provide insight into potential clinical outcomes. Ovid management will describe the exploratory biomarkers in use to measure its next-generation GABA-aminotransferase (GABA-AT) inhibitor program, OV329, which is anticipated to have a topline readout in Q3 2025. Keynote speaker: Leading pediatric neurologist and epileptologist Alexander Rotenberg, M.D., Ph.D. Professor of Neurology at Boston Children's Hospital and Harvard Medical School, and Director of the Epilepsy Monitoring Unit at Boston Children's Hospital, and the Experimental Neurophysiology Core at F.M. Kirby Center of Neurobiology Unfortunately, nearly 40 percent of people living with epilepsy continue to experience seizures despite existing medicines. OV329 is a next-generation GABA-AT inhibitor, that was rationally designed to work differently from current medicines and may offer a novel approach for patients with treatment-resistant seizures. OV329 seeks to endogenously deliver optimal levels of GABA to reduce seizures and provide a preferable safety and tolerability profile relative to the first-generation, GABA-AT inhibitor, vigabatrin. OV329 is currently completing a Phase 1 study that is evaluating its effects on multiple pharmacodynamic biomarkers, safety, tolerability, and pharmacokinetics. Interested in attending or participating remotely: To register, please visit: Registration Link A live webcast of the presentation can be accessed through the Events & Presentations section of Ovid's website at About Ovid Therapeutics Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. For more information about these and other Ovid research programs, please visit Forward-Looking Statements This press release includes certain disclosures by Ovid that contain 'forward-looking statements' including, without limitation: statements regarding the expected timing of initiation, completion, and results and data of Ovid's clinical studies; the potential use and development of OV329, OV350, OV4071 and other compounds from Ovid's library of direct activators of KCC2; and other statements that are not historical fact. You can identify forward-looking statements because they contain words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'may,' 'plan,' 'potentially,' and 'will,' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid's current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to Ovid's ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its business strategy or unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption 'Risk Factors' in Ovid's most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ('SEC'), and in subsequent and future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. Media and Investor Relations:Victoria Fort vfort@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-06-2025
- Yahoo
Dream Impact Trust Announces Voting Results of Annual Meeting of Unitholders
TORONTO, June 03, 2025--(BUSINESS WIRE)--DREAM IMPACT TRUST (TSX: (the "Trust") announced that, at its annual meeting of unitholders (the "Meeting") held today, all of the nominees for election as trustees of the Trust (the "Trustees") referred to in its management information circular for the Meeting (the "Circular") were elected. Votes cast on this matter were as follows: Nominee Votes For % Votes For Votes Withheld % Votes Withheld Amar Bhalla 7,754,302 98.71 101,589 1.29 Dr. Catherine Brownstein 7,696,342 97.97 159,549 2.03 Robert Goodall 7,752,220 98.68 103,671 1.32 Jennifer Lee Koss 7,698,437 98.00 157,454 2.00 Karine MacIndoe 7,746,987 98.61 108,904 1.39 At the Meeting, PricewaterhouseCoopers LLP was appointed as the auditor of the Trust, Dream Impact Master LP and the Trust's subsidiaries for the ensuing year, and the Trustees were authorized to fix the remuneration of the auditor. Votes cast on this matter were as follows: Votes For % Votes For Votes Withheld % Votes Withheld PricewaterhouseCoopers LLP 7,813,038 99.09 72,079 0.91 About Dream Impact Trust Dream Impact is an open-ended trust dedicated to impact investing. Dream Impact's underlying portfolio is comprised of exceptional real estate assets reported under two operating segments: development and recurring income, that would not be otherwise available in a public and fully transparent vehicle, managed by an experienced team with a successful track record in these areas. The objectives of Dream Impact are to create positive and lasting impacts for our stakeholders through our three impact verticals: environmental sustainability and resilience, attainable and affordable housing, and inclusive communities, while generating attractive returns for investors. For more information, please visit: View source version on Contacts Meaghan PelosoChief Financial Officer(416) 365-6322mpeloso@ Kim LefeverDirector, Investor Relations(416) 365-6339klefever@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
